Zymeworks (ZYME) Return on Capital Employed (2022 - 2026)
Zymeworks recorded quarterly Return on Capital Employed of 30.28% in Q1 2026, down 7.81% quarter-over-quarter from 28.08% in Q4 2025, and up 267.0% year-over-year from 8.25% in Q1 2025.
Zymeworks' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 30.28% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 267.0% year-over-year to 30.28%; the TTM figure through Mar 2026 stood at 30.28% (up 267.0% YoY), while the FY2025 annual figure was 25.53%, up 608.0% from the prior year.
- Return on Capital Employed came in at 30.28% for Q1 2026 at Zymeworks, down from 28.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 40.44% in Q3 2023 to a low of 35.44% in Q4 2024.
- A 5-year average of 10.18% and a median of 27.5% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 7357 bps in 2024 and soared 1356 bps in 2025, its largest moves.
- Zymeworks' Return on Capital Employed stood at 34.45% in 2022, then tumbled by 178 bps to 26.92% in 2023, then plunged by 32 bps to 35.44% in 2024, then advanced by 21 bps to 28.08% in 2025, then declined by 8 bps to 30.28% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 30.28%, 28.08%, and 19.57% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -30.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.28% |
| Dec 31, 2025 | -28.08% |
| Sep 30, 2025 | -19.57% |
| Jun 30, 2025 | -21.85% |
| Mar 31, 2025 | -32.94% |
| Dec 31, 2024 | -35.44% |
| Sep 30, 2024 | -33.13% |
| Jun 30, 2024 | -28.61% |
| Mar 31, 2024 | -29.11% |
| Dec 31, 2023 | -26.92% |
| Sep 30, 2023 | 40.44% |
| Jun 30, 2023 | 36.95% |
| Mar 31, 2023 | 31.56% |
| Dec 31, 2022 | 34.45% |